VBM results (follow-up > baseline).

<p>The <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0131803#pone.0131803.g002" target="_blank">Fig 2</a> represents: A) the significant increase in parahippocampus GM density, B) the increase GM density in dorsolateral prefrontal cortex as revealed by the longitudinal VBM analysis.</p

Neuropsychological tests scores at different follow ups.

<p>See text for tests abbreviation. Repeated measures ANOVA was used to compare tests mean scores at different follow ups. The p value related to the main effect of the within variable Time is reported in this Table.</p><p>Neuropsychological tests scores at different follow ups.</p

Clinical characteristics of patients at different follow ups.

<p>ARR: annualized relapse rate; EDSS: expanded disability status scale</p><p>Clinical characteristics of patients at different follow ups.</p

Baseline socio-demographic information.

<p>The table reported mean and standard deviation. Age, education and disease duration are expressed in years.</p><p>♀ = female</p><p>♂ = male.</p><p>Baseline socio-demographic information.</p

Mean number of impaired tests in patients starting natalizumab with EDSS>3 or<3.

<p>Columns represent mean (± SD) number of failed cognitive tests in patients starting natalizumab with EDSS ≤3 (black) or >3 (grey). *, <i>p</i><0.005 <i>vs</i>. baseline; #, <i>p</i><0.01 <i>vs</i>. baseline; °, <i>p</i><0.05 <i>vs</i>. EDSS >3.</p